Experimental Treatment Shows Promise for Certain Cases of Advanced NSCLC
September 23rd 2020There is no approved treatment that targets the KRAS p.G12C mutation that drives some cancers like non-small cell lung cancer. But a recent study shows how the experimental drug sotorasib sparked responses in some patients with advanced non-small cell lung cancer that harbored the mutation.
Christie Santure, B.S.N., RN, OCN, Wins CURE®'s 2020 Extraordinary Healer Award for Oncology Nursing
September 18th 2020At a virtual event Sept. 17, CURE® also named Elizabeth Farrat, B.S.N., RN, CCRN-K, the winner of its first-ever Finest Hour Award for selfless achievements in care during the COVID-19 pandemic.
Lynparza Maintenance Delays Disease Progression for Advanced BRCA-Positive Ovarian Cancer
September 3rd 2020Immediate treatment with Lynparza after standard surgery and chemotherapy should be considered for all patients with newly diagnosed stage 3 or 4 ovarian cancer that carries a BRCA gene mutation, even if residual disease remains, researchers have found.
Intensifying Rituxan for Diffuse Large B-Cell Lymphoma Treatment Does Not Improve Health Outcomes
September 2nd 2020Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.
Generic Form of Pemetrexed Approved to Treat Non-Squamous Non-Small Cell Lung Cancer
August 26th 2020The FDA has approved a generic form of the intravenous chemotherapy pemetrexed for use by itself in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not progressed following four cycles of initial platinum-based chemotherapy.
Uneven Access to Preventive Medicine Could Explain Rising Racial Inequity in Liver Cancer Death Rate
August 21st 2020After lifesaving medicine became available to treat hepatitis C virus, a risk factor for liver cancer, racial inequities in the death rate from the malignancy began a steady upward climb.
Numerous Quality-of-Life Disturbances Affect Patients with Cholangiocarcinoma, Survey Finds
July 27th 2020A survey administered by pharmaceutical company Incyte and the nonprofit Cholangiocarcinoma Foundation found that patients with bile duct cancer face more than a dozen symptoms or treatment-related side effects that negatively affect their daily lives.
Staying Cool: Cold Caps and Hair Preservation in Cancer
July 16th 2020In this episode of the “CURE Talks Cancer” podcast, we spoke with breast cancer specialist Dr. Julie Nangia about the increase of popularity in the use of devices known as cold caps to help patients with solid tumors receiving treatment for their disease keep more of their hair from falling out.
FDA Approves Keytruda as Initial Treatment for Advanced Colorectal Cancer with DNA Repair Defects
June 30th 2020Keytruda bested chemotherapy, delaying disease progression or death by 40%, in a clinical trial that led to the drug’s approval for use as a single initial treatment for patients with colorectal cancer.
Survivors Tell Stories of Cancer and Coronavirus in 12th Annual Performance by Visible Ink
June 29th 2020In its first virtual performance, the Visible Ink writing therapy program at Memorial Sloan Kettering Cancer Center shared works by patients and staff members that touched on the COVID-19 pandemic and were interpreted by celebrity actors, singers and dancers.
Kathy LaTour, CURE Magazine Co-Founder, Author and Breast Cancer Survivor, Dies on June 19, 2020
June 23rd 2020“Anyone who met my mother was touched by her spirit. She challenged people to be curious, to seek more, to learn more and to challenge themselves,” LaTour’s daughter, Kirtley Perkins, wrote on Facebook.
FDA Approves Lynparza for Certain Pretreated Patients with Metastatic Prostate Cancer
May 20th 2020The Food and Drug Administration gave the green light to the PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer that has a defective DNA-repair process and has progressed after treatment with the novel hormone-controlling drugs Xtandi (enzalutamide) or Zytiga (abiraterone acetate).